Search Results for “EC” – Page 137 – media

New Male Contraceptive Pill With No Side Effects

At present, condoms and vasectomy are the only birth control methods available for men. Even though many male hormonal drugs target the production of sperm, they also affect the natural hormones in men.
- Source: Ddu
- 1,213
- June 7, 2018
Clinical Trials contraceptive drugs Researches
Lynparza and Zytiga Combo Effective Against Prostate Cancer

Along with new drug partner Merck, the British drugmaker displayed results showing that adding Lynparza to Johnson & Johnson prostate cancer fighter Zytiga was a more potent disease-fighter than Zytiga alone. As compared to a time-frame of 8.2 months for solo Zytiga, the combo effectively prevented disease progression for 13.8 months.
- Source: Ddu
- 758
- June 6, 2018
AstraZeneca Clinical Trials Company Insight prostate cancer
Pneumonia Detection mHealth Wearable

Researchers are testing an mHealth wearable used for patients with asthma to see if the patch can help care teams detect pneumonia in patients undergoing radiation treatment for lung cancer.
- Source: mHealth Intelligence
- 844
- June 5, 2018
Clinical Trials mHealth pneumonia wearables
Parachute Health Received $9.5 Million Funding for ePrescribing Platform

The New York-based startup is aiming to digitize the equipment and to make the process easier through the ePrescribing platform. That way, the hospital doesn't spend time on faxing to communicate the order, and the patients and healthcare suppliers can get it quicker than they might have otherwise.
- Source: Business Insider
- 501
- June 5, 2018
Company Insight EHR
Data From Grail Shows Early Detection Of Cancer

Three of the company’s prototype genome-sequencing assays were evaluated using samples from lung cancer patients. Early support for the concept was demonstrated with detection rates ranging from 38% to 51% in participants in participants with early-stage lung cancer at 98% specificity.
- Source: FierceBiotech
- 518
- June 5, 2018
cancer cells genome Researches
NIPT to Detect Chromosomal Disorders in Unborn Babies

A study conducted in ten hospitals found that NIPT (Non-Invasive Prenatal Screening Test), was safer, more accurate and more effective in detecting chromosomal abnormalities in unborns, compared to conventional marker tests and ultrasound studies.
- Source: Ddu
- 560
- June 5, 2018
Down's syndrome NIPT pregnancy Researches
Ibuprofen Affects Daughters’ Fertility In Future

Consumption of commonly available Ibuprofen for just two days by pregnant women during their first 24 weeks may reduce the fertility of their unborn child in future if it is a girl. The child’s egg production after puberty could be affected. This shocking discovery was unveiled by a research team from the National Institute for Health and Medical Research in France.
- Source: Ddu
- 606
- June 4, 2018
Ibuprofen pregnancy Researches
Niti Aayog Planning to Improve Indian Medical Devices Sector

Niti Aayog is focusing on proposals to encourage domestic manufacturing of medical devices following orders from the Prime Minister's Office, said the expert. The meeting was focused on identifying the problems in local manufacturing and quality of the devices produced in India and also to spot the solution for the issues.
- Source: Ddu
- 839
- May 31, 2018
India Market Views medical device
Packaging Error Prompts Allergan to Recall Sample Packs of Taytulla Contraceptive Pills

A voluntary nationwide recall of 168,768 physician sample packs of Taytulla capsules was issued by the Dublin-based drug maker. The action came in the wake of a discovery by a physician of a package in which four non-hormonal placebo capsules replaced active capsules in the first four days of therapy.
- Source: Ddu
- 871
- May 30, 2018
Company Insights contraceptive drugs
Market for Mobile Health Technology To Exceed USD 28 Billion In 2018

According to an estimate by SNS Telecom & IT, the present vibrant ecosystem is bound to trigger the growth of the mHealth market at more than USD 28 billion in 2018. In spite of impediments presented by regulation, patient acceptance and privacy concerns, the sector is expected to clock a CAGR of around 30 percent over the next three years.
- Source: Ddu
- 906
- May 30, 2018
Market Views mHealth

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.